US FDA extends review of Centocor's ustekinumab
This article was originally published in Scrip
Executive Summary
The US FDAhas extended by three months its review of Centocor's (Johnson & Johnson) novel monoclonal antibody ustekinumab (proposed trade name Stelara) for psoriasis. The new user fee date is in December.